Hearing aid support for patients with DR-TB in Ethiopia.

IF 1.3 Q4 RESPIRATORY SYSTEM Public Health Action Pub Date : 2022-06-21 DOI:10.5588/pha.21.0068

G Teferra, K Teklemariam, D F Wares, C Negeri, A Bedru

{"title":"Hearing aid support for patients with DR-TB in Ethiopia.","authors":"G Teferra, K Teklemariam, D F Wares, C Negeri, A Bedru","doi":"10.5588/pha.21.0068","DOIUrl":null,"url":null,"abstract":"Setting: Previous and current patients with drug-resistant TB (DR-TB) who had documented treatment-related hearing impairment due to second-line injectable (SLI) use were identified from different DR-TB treatment initiation centres in Ethiopia.Objective: To assess selected patients with DR-TB for eligibility for hearing aids and provide hearing aids to 10 eligible patients.Design: This was an observational cohort study. Patients were followed up for 8 months, with hearing assessments conducted at 1, 3 and 8 months to objectively assess hearing capacity.Results: Of 12 patients assessed for hearing aids eligibility, 10 were fitted with hearing aids (type XTM XP P4) and followed up for 8 months. \"Formal\" improvement was observed only in one patient. However, \"general quality of life\" appeared to be improved in nine patients.Conclusion: Minimal \"formal\" improvement was observed. However, the study was too small to say whether hearing aids should, or should not, be recommended as a public health measure. This needs a larger better controlled follow-up study. The all-oral DR-TB treatment regimens should be used for all patients with DR-TB in Ethiopia. However, as a proportion of patients with DR-TB are likely to continue receiving SLIs in the foreseeable future, they will require close audiometry assessment and appropriate care.","PeriodicalId":46239,"journal":{"name":"Public Health Action","volume":"12 2","pages":"74-78"},"PeriodicalIF":1.3000,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176189/pdf/i2220-8372-12-2-74.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Action","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/pha.21.0068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 2

Abstract

Setting: Previous and current patients with drug-resistant TB (DR-TB) who had documented treatment-related hearing impairment due to second-line injectable (SLI) use were identified from different DR-TB treatment initiation centres in Ethiopia.

Objective: To assess selected patients with DR-TB for eligibility for hearing aids and provide hearing aids to 10 eligible patients.

Design: This was an observational cohort study. Patients were followed up for 8 months, with hearing assessments conducted at 1, 3 and 8 months to objectively assess hearing capacity.

Results: Of 12 patients assessed for hearing aids eligibility, 10 were fitted with hearing aids (type XTM XP P4) and followed up for 8 months. "Formal" improvement was observed only in one patient. However, "general quality of life" appeared to be improved in nine patients.

Conclusion: Minimal "formal" improvement was observed. However, the study was too small to say whether hearing aids should, or should not, be recommended as a public health measure. This needs a larger better controlled follow-up study. The all-oral DR-TB treatment regimens should be used for all patients with DR-TB in Ethiopia. However, as a proportion of patients with DR-TB are likely to continue receiving SLIs in the foreseeable future, they will require close audiometry assessment and appropriate care.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

埃塞俄比亚为耐药结核病患者提供助听器支持。

背景:从埃塞俄比亚不同的耐药结核病开始治疗中心确定了以前和现在的耐药结核病患者，这些患者由于使用二线注射(SLI)而记录有治疗相关的听力障碍。目的:评估选定的耐药结核病患者是否符合配戴助听器的条件，并为10例符合条件的患者提供助听器。设计:这是一项观察性队列研究。随访8个月，分别于1、3、8个月进行听力评估，客观评价患者听力。结果:12例患者中，10例患者配戴助听器(XTM XP P4型)，随访8个月。只有一名患者出现“正式”改善。然而，9名患者的“总体生活质量”似乎有所改善。结论:观察到最小的“正式”改善。然而，这项研究规模太小，无法说明助听器是否应该被推荐作为一项公共卫生措施。这需要更大规模、更好的对照随访研究。埃塞俄比亚的所有耐药结核病患者都应采用全口服耐药结核病治疗方案。然而，由于一部分耐药结核病患者可能在可预见的未来继续接受特殊语言抑制剂治疗，他们将需要密切的听力评估和适当的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Public Health Action RESPIRATORY SYSTEM-

自引率

0.00%

发文量

期刊介绍： Launched on 1 May 2011, Public Health Action (PHA) is an official publication of the International Union Against Tuberculosis and Lung Disease (The Union). It is an open access, online journal available world-wide to physicians, health workers, researchers, professors, students and decision-makers, including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. PHA is a peer-reviewed scholarly journal that actively encourages, communicates and reports new knowledge, dialogue and controversy in health systems and services for people in vulnerable and resource-limited communities — all topics that reflect the mission of The Union, Health solutions for the poor.